Mira Pharmaceuticals, Inc.

MIRA Nasdaq SEC CIK 1904286
Follow Mira Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$1.4M −25.1% vs same quarter last year
EPS, diluted −$0.03 +97.5% vs same quarter last year
Operating cash flow −$1.3M −18.4% vs same quarter last year
Net income by quarter
−$2.4M
−$1.8M
−$1.5M
−$1.1M
−$6M
−$1.2M
−$1.2M
−$1.4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income5 fiscal years
−$15M−$10M−$5M$0FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$10.4M
FY24−$7.9M
FY23−$12M
FY22−$7.1M
FY21-